Loading insider details...
Beta
Latest Form 4 (Jul 9, 2026): Exercise/Conversion of 32,375 SNDX shares, $206.6K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 9, 2026 | Syndax Pharmaceuticals Inc (SNDX) | Exercise/Conversion | 32,375 | $206.6K |
| Jun 2, 2026 | Syndax Pharmaceuticals Inc (SNDX) | Sale | 6,847 | $130.0K |
| Mar 25, 2026 | Pyxis Oncology, Inc. (PYXS) | Grant/Award | 45,867 | n/a |
| Feb 10, 2026 | Syndax Pharmaceuticals Inc (SNDX) | Sale | 17,159 | $360.8K |
| Feb 6, 2026 | Syndax Pharmaceuticals Inc (SNDX) | Grant/Award | 73,000 | n/a |
| Sep 8, 2025 | Syndax Pharmaceuticals Inc (SNDX) | Exercise/Conversion | 157,307 | $1.71M |
| Jul 18, 2025 | Syndax Pharmaceuticals Inc (SNDX) | Sale | 7,534 | $70.0K |
| Apr 2, 2025 | Pyxis Oncology, Inc. (PYXS) | Grant/Award | 36,979 | $36.2K |
| Mar 17, 2025 | Syndax Pharmaceuticals Inc (SNDX) | Exercise/Conversion | 6,074 | $43.7K |
| Mar 6, 2025 | Syndax Pharmaceuticals Inc (SNDX) | Exercise/Conversion | 7,814 | $56.3K |